Oasis Donor Site Wounds Post-Market Study

Recruiting now · Not applicable

Conditions studied: Surgical Wound, Wound, Wounds and Injuries, Wound Heal

In brief

The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom. Oasis ECM is commercially available for the treatment of partial and full-thickness skin wounds, including chronic wounds, wounds from trauma, and wounds that occur during surgery, such as donor site wounds. The ability of the Oasis ECM to promote the healing of donor site wounds will be evaluated in this study. About 40 patients (20 in each arm) over 16 years old will be involved in this study at one center in the United Kingdom.

Key facts

Study ID

NCT04079348

Run by

Cook Biotech Incorporated

People needed

40

Starts

2020-11-01

Expected to finish

2025-12-01

Last updated by the study team

2024-12-17

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has a split thickness skin graft (STSG) donor site wound no greater than 14 x 20 cm in size requiring placement of a covering material.
• Has at least 24 hours to consent to study participation.

You may not qualify if…

• Age < 16 years
• Patients who, in the opinion of the investigator, have co-morbidities that impair wound healing, such as:
• Chronic inflammatory skin condition
• Chronic liver failure
• Chronic renal failure
• Blood-borne viruses (Hep B, Hep C, HIV)
• Peripheral vascular disease
• Clinically significant anaemia
• Uncontrolled diabetes
• Need for use of the same harvest site (re-cropping)
• History of radiation therapy to proposed donor site
• Chronic use of medications known to impair wound healing
• Chronic use of opioids or neuropathic pain agents
• Suspected cellulitis, osteomyelitis or septicaemia
• Patients undergoing haemodialysis
• Patients requiring spinal/regional block
• Patients on current anti-coagulant therapy
• Unable or unwilling to provide informed consent
• Unable or unwilling to comply with the study follow-up schedule, and procedures
• Simultaneously participating in another investigational drug or device study (patient must have completed the follow-up phase for the primary endpoint of any previous study at least 30 days prior to enrolment in this study)
• Allergy or hypersensitivity to materials that are porcine-based
• Cultural or religious objection to the use of pig or porcine products
• Known intolerance/allergy to standard wound care products
• Presence of a local infection at the donor site and/or systemic infection

Where it is running

• Manchester University NHS Foundation Trust — Manchester, England, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.